Follicular Lymphoma

Conference Coverage

EZH2 inhibitor can produce durable responses

ORLANDO, FL—Updated results of a phase 1 study suggest the EZH2 inhibitor tazemetostat (EPZ-6438) can produce durable responses in patients with...


Trial of ofatumumab in FL stopped early

Photo courtesy of GSK Genmab A/S said it is stopping a phase 3 trial of ofatumumab in follicular lymphoma (FL) after a planned interim analysis...

Conference Coverage

Reprogramming the immune system

showing Hodgkin lymphoma NEW YORK—Using a 3-pronged approach to reprogram the immune system—inhibition of critical pathways, activation of others...